Salvatore Tafuto

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Simron Singh, Daniel Halperin, Sten Myrehaug et al. · The Lancet · 2024 · 250 citations · Full text

Grade 2–3, Endocrine Oncology, Long-acting Octreotide +10

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

Jaume Capdevila, Nicola Fazio, Carlos López et al. · Journal of Clinical Oncology · 2021 · 103 citations · Full text

Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms

James C. Yao, Jonathan Strosberg, Nicola Fazio et al. · Endocrine Related Cancer · 2021 · 102 citations

Capecitabine plus oxaliplatin for the first‐line treatment of elderly patients with metastatic colorectal carcinoma

Pasquale Comella, D. Natale, A. Farris et al. · Cancer · 2005 · 91 citations · Full text

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Sara Pusceddu, Claudio Vernieri, Massimo Di Maïo et al. · Gastroenterology · 2018 · 87 citations · Full text

Oncology, Pancreatic Cancer, Medicine +8